Trial Profile
Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ECOM
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record
- 04 May 2011 New trial record